Dataset Information

DIA anaylsis for human plasma in MI patitents

ABSTRACT: A total of 386 patients were enrolled from May 2019 to May 2022 in TEDA International Cardiovascular Hospital, Tianjin, China. This study was approved by Institutional Review Board (IRB) at TEDA International cardiovascular hospital, Tianjin, china, and informed consent was obtained from all patients recruited in this study. All patients were informed of all the aspects of the study. STEMI refers to designate MI in patients with chest discomfort or other ischaemia symptoms, who develop new ST-segment elevations in two contiguous leads or new bundle branch blocks with ischaemia repolarization patterns as an ST-elevation MI. Patients present without ST-segment elevation were designated as having NSTEMI (13). Patients without ST-segment elevation exert symptoms suggestive of cardiac ischemia without elevated biomarker values can be diagnosed as having UA(5, 13). The inclusion and exclusion criteria of STEMI, NSTEMI and UA patients were according to the guidelines outlined by the 2017 European Society of Cardiology (ESC)(14). The control subjects were recruited from patients that underwent conventional coronary angiography for atypical chest discomfort(15). Finally, 182 patients were included in STEMI group, 80 in NSTEMI group, and 62 in UA group. Additionally, after matching the age and gender, 62 subjects with normal coronary arteries were identified as Control (CON). All treatment and management measures were monitored by the attending physicians. Further, the clinical information was collected, including age, gender, body mass index (BMI), risk factors such as hypertension, diabetes, dyslipidemia, and smoke. The vessel lesion and laboratory data were also collected.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

SUBMITTER: Hongmei Xue

LAB HEAD: Guowei He

PROVIDER: PXD056463 | Pride | 2025-07-14

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 41

Publications

Data-Independent Acquisition Proteomics Identifies Plasma Prostaglandin-H2 D-Isomerase as an Early Diagnostic Biomarker for STEMI and NSTEMI.

Xue Hong-Mei HM Hou Hai-Tao HT Song Yu Y Chen Huan-Xin HX Zhang Yun-Qiang YQ Sun Wen-Tao WT Zhou Jie J Zhou Xiao-Lin XL Sun Na N Yang Qin Q He Guo-Wei GW

Molecular & cellular proteomics : MCP 20250523 7

Myocardial infarction (MI), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), remains a leading cause of death worldwide. This study aimed to identify the early diagnostic biomarkers for STEMI and NSTEMI. Plasma samples from 386 patients were classified into four groups: control (CON) (n = 62), unstable angina (UA) (n = 62), STEMI (n = 182), and NSTEMI (n = 80). The protein profiles were analyzed using data-independent acqui ...[more]

PMID: 40414290

Similar Datasets

Project description:Malaria is by far the world’s most significant tropical infectious disease and over the last a few decades large-scale malaria epidemics have happened in almost all continents. Plasmodium falciparum and Plasmodium vivax account for over 90% of the total malaria cases worldwide. The estimated number of annual clinical cases of vivax malaria is even higher than that of falciparum malaria, but yet the morbidity associated with this infection and its spectrum of disease is largely neglected. Identification of serum/plasma proteins, which exhibit altered abundance at the onset and during the acute phase of any infection, could be informative to understand the pathobiology of different infectious diseases and host responses against the invading pathogens. To this end, in recent years, quite a few research groups including us have investigated alterations in serum/plasma proteome in severe and non-severe falciparum malaria (and also vivax malaria) to study malaria pathogenesis. In all these studies, serum/plasma proteome of the malaria patients have been analyzed during the febrile stages of the infection, either at the onset of the disease or at the fastigium stage. However, temporal profiling of serum/plasma proteome during acute and remission stages in malaria, which can provide snapshots of the transient and enduring alterations in serum proteome during the febrile, defervescence and convalescent stages has not been reported hitherto. Here, we report, for the first time, serum proteomic alterations in a longitudinal cohort of P. vivax infected patients to elucidate host responses when fever is established (temperature of the body reaches above higher normal level), during the stage when the temperature comes down to normal, and also during the gradual recovery of health after the illness. The three stages discussed in our study have been categorically chosen depending upon the clinical course of uncomplicated vivax malaria. Analysis of the early febrile stage represents host proteome profile immediately after onset of the infection, without any effect of anti-malarial drugs. The second, defervescence stage, reflects any immediate change in blood proteome at early recovery phase, while the convalescent stage indicates a phase after administration of 14 days radical cure treatment with primaquine and a complete recovery, when none of the patients displayed any apparent symptoms of malaria. We have also performed an extensive quantitative proteomics analysis to compare the serum proteome profiles of vivax malaria patients with low and moderately-high parasitemia with healthy community controls. Isobaric tags for relative and absolute quantitation (iTRAQ) and 2-D fluorescence difference gel electrophoresis (2D-DIGE)-based quantitative proteomics approaches were used in the discovery-phase of the study, and some selected differentially abundant serum proteins were validated further by using ELISA. Interestingly, some of the serum proteins like Serum amyloid A, Apolipoprotein A1, C-reactive protein, Titin and Haptoglobin, were found to be sequentially altered with respect to increased parasite counts, while many of the quantified candidates such as Hemopexin, Vitronectin, Clusterin and Apolipoprotein E exhibited nearly equal levels of differential serum abundance in different parasitemic malaria patients. Analysis of a longitudinal cohort of malaria patients indicated reversible alterations in serum levels of some proteins such as Haptoglobin, Apolipoprotein E, Apolipoprotein A1, Carbonic anhydrase 1, and Hemoglobin subunit alpha upon treatment; however, the levels of a few other proteins did not return to the baseline even during the convalescent phase of the infection. Identification of the differentially abundant serum proteins and associated physiological pathways in vivax malaria along with phase-specific protein profiles during the acute and convalescent phases of the infection can effectively enhance our understanding of P. vivax disease biology and host immune responses.

			Action	DRS
	0755-DDA-1.raw	Raw
	0755-DDA-10.raw	Raw
	0755-DDA-2.raw	Raw
	0755-DDA-3.raw	Raw
	0755-DDA-4.raw	Raw